乙型肝炎治疗的最新研究和知识

Q4 Immunology and Microbiology Journal of Bacteriology and Virology Pub Date : 2020-09-30 DOI:10.4167/JBV.2020.50.3.175

Hye-won Lee, Yongwook Choi, Y. Park

{"title":"乙型肝炎治疗的最新研究和知识","authors":"Hye-won Lee, Yongwook Choi, Y. Park","doi":"10.4167/JBV.2020.50.3.175","DOIUrl":null,"url":null,"abstract":"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/ license/by-nc/3.0/). Hepatitis B virus (HBV) infection is a major public health problem, with some 250 million people currently at high risk of developing chronic liver diseases. The current antiviral treatment for chronic hepatitis B (CHB) is effective in controlling viral replication but fails to achieve a complete cure. Since the identification of sodium taurocholate cotransport polypeptide (NTCP) as an HBV receptor, anti-HBV drugs targeting viral entry, capsid assembly, cccDNA, transcription, and secretion have been developed. In this paper, the potential inhibitors in various steps of the HBV life cycle are summarized.","PeriodicalId":39739,"journal":{"name":"Journal of Bacteriology and Virology","volume":"50 1","pages":"175-180"},"PeriodicalIF":0.0000,"publicationDate":"2020-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Recent Research and Knowledge on Treatment for Hepatitis B\",\"authors\":\"Hye-won Lee, Yongwook Choi, Y. Park\",\"doi\":\"10.4167/JBV.2020.50.3.175\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/ license/by-nc/3.0/). Hepatitis B virus (HBV) infection is a major public health problem, with some 250 million people currently at high risk of developing chronic liver diseases. The current antiviral treatment for chronic hepatitis B (CHB) is effective in controlling viral replication but fails to achieve a complete cure. Since the identification of sodium taurocholate cotransport polypeptide (NTCP) as an HBV receptor, anti-HBV drugs targeting viral entry, capsid assembly, cccDNA, transcription, and secretion have been developed. In this paper, the potential inhibitors in various steps of the HBV life cycle are summarized.\",\"PeriodicalId\":39739,\"journal\":{\"name\":\"Journal of Bacteriology and Virology\",\"volume\":\"50 1\",\"pages\":\"175-180\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-09-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Bacteriology and Virology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4167/JBV.2020.50.3.175\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Immunology and Microbiology\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Bacteriology and Virology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4167/JBV.2020.50.3.175","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Immunology and Microbiology","Score":null,"Total":0}

引用次数: 0

摘要

这是一篇根据知识共享署名非商业许可条款发布的开放获取文章(http://creativecommons.org/乙型肝炎病毒（HBV）感染是一个主要的公共卫生问题，目前约有2.5亿人面临患慢性肝病的高风险。目前针对慢性乙型肝炎（CHB）的抗病毒治疗在控制病毒复制方面是有效的，但未能完全治愈。自从牛磺胆酸钠协同转运多肽（NTCP）被鉴定为HBV受体以来，针对病毒进入、衣壳组装、cccDNA、转录和分泌的抗HBV药物已经被开发出来。本文综述了HBV生命周期各个阶段的潜在抑制剂。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Recent Research and Knowledge on Treatment for Hepatitis B

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/ license/by-nc/3.0/). Hepatitis B virus (HBV) infection is a major public health problem, with some 250 million people currently at high risk of developing chronic liver diseases. The current antiviral treatment for chronic hepatitis B (CHB) is effective in controlling viral replication but fails to achieve a complete cure. Since the identification of sodium taurocholate cotransport polypeptide (NTCP) as an HBV receptor, anti-HBV drugs targeting viral entry, capsid assembly, cccDNA, transcription, and secretion have been developed. In this paper, the potential inhibitors in various steps of the HBV life cycle are summarized.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Bacteriology and Virology Immunology and Microbiology-Immunology

CiteScore

0.80

自引率

0.00%

发文量